Latest news
Why CelLBxHealth (LSE:CLBX) Is Drawing Fresh Attention in Cancer Research - Kalkine MediaKalkine Media · Tue, 04 Aug 2026 05:43:00 GMTParsortix CTC platform detects ADC targets in breast and ovarian cancer - Manufacturing ChemistManufacturing Chemist · Mon, 03 Aug 2026 12:37:56 GMTParsortix study shows promise for ADC target detection - PharmaTimesPharmaTimes · Mon, 03 Aug 2026 10:54:03 GMTCelLBxHealth’s Parsortix® Platform Validated in Peer-Reviewed Study for Detecting ADC Targets on Circulating Tumor Cells in Breast and Ovarian Cancer - Kalkine MediaKalkine Media · Mon, 03 Aug 2026 06:01:47 GMTCellbxhealth plc Uses Parsortix Platform to Detect Adc-Relevant Targets on Circulating Tumour Cells from Breast and Ovarian Cancer Patients - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 06:00:00 GMTCelLBxHealth’s Parsortix platform bolsters ADC monitoring credentials in peer‑reviewed CTC study - TipRanksTipRanks · Sun, 02 Aug 2026 07:00:00 GMT